No significant strengths identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TECHBio-Techne Corporation | 10.9B | 69.96 | 152.09 | 5.23% | 6.41% | 3.97% | 2.35% | 0.23 |
| SPRYARS Pharmaceuticals, Inc. | 1.1B | 11.09 | 142.00 | 2970.63% | -56.06% | -54.21% | 1.18% | 0.00 |
| VCYTVeracyte, Inc. | 3.24B | 41.00 | 132.26 | 23.46% | 6.12% | 2.41% | 1.97% | 0.04 |
| CSBRChampions Oncology, Inc. | 99.56M | 7.17 | 21.73 | 13.54% | 4.32% | 59.65% | 7.03% | 1.62 |
| MDXGMiMedx Group, Inc. | 851.59M | 5.75 | 20.54 | 8.52% | 10.38% | 17.09% | 7.58% | 0.13 |
| LTRNLantern Pharma Inc. | 39.26M | 3.51 | -0.00 | -197.36% | 0.01 | |||
| SEERSeer, Inc. | 107.44M | 1.91 | -1.37 | -8.13% | -486.02% | -29.19% | 0.08 | |
| IMDXInsight Molecular Diagnostics Inc. | 189.76M | 6.62 | -1.42 | 25.15% | -13.81% | -14.81% |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 |
| Revenue Growth % | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin % | - | - | - |
| Gross Profit Growth % | - | - | - |
| Operating Expenses | 976.35K | 1.34M | 3.09M |
| OpEx % of Revenue | - | - | - |
| Selling, General & Admin | 421.18K | 1.34M | 3.09M |
| SG&A % of Revenue | - | - | - |
| Research & Development | 175.32K | 72.05K | 0 |
| R&D % of Revenue | - | - | - |
| Other Operating Expenses | 379.85K | -72.05K | 0 |
| Operating Income | -976.35K | -1.34M | -3.09M |
| Operating Margin % | - | - | - |
| Operating Income Growth % | - | -0.37% | -1.3% |
| EBITDA | -596K | 4.47M | -11.65M |
| EBITDA Margin % | - | - | - |
| EBITDA Growth % | - | 8.51% | -3.6% |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 |
| EBIT | -596K | 4.47M | -11.65M |
| Net Interest Income | 4.32M | 5.8M | -343K |
| Interest Income | 4.32M | 5.81M | 548.68K |
| Interest Expense | 0 | 8.97K | 891.62K |
| Other Income/Expense | 379.97K | 5.8M | -9.45M |
| Pretax Income | -596.37K | 4.46M | -12.54M |
| Pretax Margin % | - | - | - |
| Income Tax | 626 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% |
| Net Income | -597K | 4.46M | -12.54M |
| Net Margin % | - | - | - |
| Net Income Growth % | - | 8.48% | -3.81% |
| Net Income (Continuing) | -597K | 4.46M | -12.54M |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| EPS (Diluted) | -0.07 | 0.54 | -1.52 |
| EPS Growth % | - | 8.46% | -3.81% |
| EPS (Basic) | -0.07 | 0.54 | -1.52 |
| Diluted Shares Outstanding | 8.24M | 8.24M | 8.24M |
| Basic Shares Outstanding | 8.24M | 8.24M | 8.24M |
| Dividend Payout Ratio | - | - | - |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Total Current Assets | 22.54K | 46.17K | 147.99K |
| Cash & Short-Term Investments | 38 | 11.17K | 3.63K |
| Cash Only | 38 | 11.17K | 3.63K |
| Short-Term Investments | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 36.5K |
| Days Sales Outstanding | - | - | - |
| Inventory | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - |
| Other Current Assets | 0 | 0 | -36.5K |
| Total Non-Current Assets | 0 | 0 | 0 |
| Property, Plant & Equipment | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Long-Term Investments | 299M | 19.9M | 6.67M |
| Other Non-Current Assets | -303.9M | -24.87M | -6.67M |
| Total Assets | 22.54K | 46.17K | 147.99K |
| Asset Turnover | - | - | - |
| Asset Growth % | - | 1.05% | 2.21% |
| Total Current Liabilities | 151.33K | 534.03K | 1.69M |
| Accounts Payable | 122.73K | 172.77K | 310.22K |
| Days Payables Outstanding | - | - | - |
| Short-Term Debt | 27.97K | 360.64K | 1.27M |
| Deferred Revenue (Current) | 0 | 0 | 0 |
| Other Current Liabilities | 626 | 626 | 111.03K |
| Current Ratio | 0.15x | 0.09x | 0.09x |
| Quick Ratio | 0.15x | 0.09x | 0.09x |
| Cash Conversion Cycle | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 |
| Total Liabilities | 151.33K | 534.03K | 1.69M |
| Total Debt | 27.97K | 360.64K | 1.27M |
| Net Debt | 27.93K | 349.46K | 1.26M |
| Debt / Equity | - | - | - |
| Debt / EBITDA | - | 0.08x | - |
| Net Debt / EBITDA | - | 0.08x | - |
| Interest Coverage | - | -149.47x | -3.46x |
| Total Equity | -128.79K | -487.86K | -1.54M |
| Equity Growth % | - | -2.79% | -2.16% |
| Book Value per Share | -0.02 | -0.06 | -0.19 |
| Total Shareholders' Equity | -128.79K | -487.86K | -1.54M |
| Common Stock | 221.5K | 22K | 22K |
| Retained Earnings | -1.11M | -1.47M | -2.78M |
| Treasury Stock | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Cash from Operations | -142.91K | 11.14K | -265.19K |
| Operating CF Margin % | - | - | - |
| Operating CF Growth % | - | 1.08% | -24.81% |
| Net Income | -597.12K | -359.07K | -1.31M |
| Depreciation & Amortization | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 0 | 0 |
| Working Capital Changes | 454.21K | 370.21K | 1.04M |
| Change in Receivables | 400K | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 |
| Change in Payables | 102.73K | 50.04K | 0 |
| Cash from Investing | -4.9M | 284.92M | 13.78M |
| Capital Expenditures | -4.9M | -75.9K | 0 |
| CapEx % of Revenue | - | - | - |
| Acquisitions | - | - | - |
| Investments | - | - | - |
| Other Investing | 0 | 284.99M | 0 |
| Cash from Financing | 4.85M | -284.76M | 257.64K |
| Debt Issued (Net) | - | - | - |
| Equity Issued (Net) | - | - | - |
| Dividends Paid | 0 | 0 | 0 |
| Share Repurchases | - | - | - |
| Other Financing | 4.11M | 0 | -1.71M |
| Net Change in Cash | - | - | - |
| Free Cash Flow | -5.04M | -653.11K | -265.19K |
| FCF Margin % | - | - | - |
| FCF Growth % | - | 0.87% | 0.59% |
| FCF per Share | -0.61 | -0.08 | -0.03 |
| FCF Conversion (FCF/Net Income) | 0.24x | 0.00x | 0.02x |
| Interest Paid | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 1.01K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Interest Coverage | - | -149.47x | -3.46x |
| FCF Conversion | 0.24x | 0.00x | 0.02x |
Aspire Biopharma Holdings, Inc. (ASBPW) reported $0.0M in revenue for fiscal year 2024.
Aspire Biopharma Holdings, Inc. (ASBPW) grew revenue by 0.0% over the past year. Growth has been modest.
Aspire Biopharma Holdings, Inc. (ASBPW) reported a net loss of $31.7M for fiscal year 2024.
Aspire Biopharma Holdings, Inc. (ASBPW) had negative free cash flow of $3.5M in fiscal year 2024, likely due to heavy capital investments.